Latest News and Press Releases

- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a favorable safety profile to date and the potential to significantly...

Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer

Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference

NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...

SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...

Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting

$120M financing will support advancement of ground-breaking regenerative cell therapies for chronic CNS disorders

Neurona Therapuetics presentation at upcoming Oppenheimer 34th Annual Healthcare Lifesciences Conference

Neurona Therapeutics presents new positive clinical data from 1st cohort in Ph I/II Trial of NRTX-1001 for drug reistant focal epilepsy at AES meeting

First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress